PYC Therapeutics Ltd
ASX:PYC

Watchlist Manager
PYC Therapeutics Ltd Logo
PYC Therapeutics Ltd
ASX:PYC
Watchlist
Price: 1.36 AUD 0.37%
Market Cap: 793.2m AUD

Operating Margin
PYC Therapeutics Ltd

-183.7%
Current
-162%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-183.7%
=
Operating Profit
-48.5m
/
Revenue
26.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
AU
PYC Therapeutics Ltd
ASX:PYC
793.2m AUD
-184%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
334.3B USD
30%
US
Amgen Inc
NASDAQ:AMGN
158.5B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
134.7B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.2B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
124.6B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
58.7B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41.8B USD
-5%

PYC Therapeutics Ltd
Glance View

Market Cap
793.2m AUD
Industry
Biotechnology

PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The firm develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The firm's discovery and laboratory operations are located in Australia.

PYC Intrinsic Value
0.66 AUD
Overvaluation 52%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-183.7%
=
Operating Profit
-48.5m
/
Revenue
26.4m
What is the Operating Margin of PYC Therapeutics Ltd?

Based on PYC Therapeutics Ltd's most recent financial statements, the company has Operating Margin of -183.7%.

Back to Top